Boehringer Ingelheim Accelerates NGS-Driven Cell Line Characterization with Genedata

The development of safe and efficacious therapeutic antibodies depends on robust cell line characterization and confident decision-making around critical quality attributes (CQAs). While next-generation sequencing (NGS) enables deep genomic analysis of production clones, even from minimal sample material, the resulting data can be complex and challenging to interpret in a development context. 

In this case study, learn how Boehringer Ingelheim leveraged Genedata Selector^®, part of the Genedata Biopharma Platform, to accelerate the interpretation of NGS-based characterization data. Automated analysis delivers faster, actionable insights — supporting informed decisions and rapid identification of atypical product attributes impacting developability, efficacy, and safety.